We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

196 hedge funds and large institutions have $1.97B invested in Pacira BioSciences in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 84 increasing their positions, 54 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

56% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 54

25% more call options, than puts

Call options by funds: $23.1M | Put options by funds: $18.5M

14% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 29

2% more funds holding

Funds holding: 192 → 196 (+4)

5% more capital invested

Capital invested by funds: $1.87B → $1.97B (+$93M)

6.75% less ownership

Funds ownership: 109.53% → 102.79% (-6.7%)

Holders
196
Holders Change
+4
Holders Change %
+2.08%
% of All Funds
4.89%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.12%
New
33
Increased
84
Reduced
54
Closed
29
Calls
$23.1M
Puts
$18.5M
Net Calls
+$4.57M
Net Calls Change
-$2.33M

Top Buyers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
+$32.2M
2
Millennium Management
Millennium Management
New York
+$27.5M
3
EVM
Eaton Vance Management
Massachusetts
+$19M
4
GPP
Great Point Partners
Connecticut
+$13.9M
5
CHP
Castle Hook Partners
New York
+$13.7M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$44.3M
2
PC
PointState Capital
New York
-$29.4M
3
CCM
Cadian Capital Management
New York
-$28M
4
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$23M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Tudor Investment Corp
151
Tudor Investment Corp
Connecticut
$233K -$23M -496,583 -99%
TFCP
152
Twin Focus Capital Partners
Massachusetts
$215K – – –
SM
153
Sabby Management
Florida
$209K +$204K +4,390 New
SCM
154
Schnieders Capital Management
California
$201K +$195K +4,210 New
BFM
155
Boothbay Fund Management
New York
$201K +$196K +4,218 New
HI
156
HBK Investments
Texas
$200K +$195K +4,200 New
LTFS
157
Ladenburg Thalmann Financial Services
Florida
$196K -$3.99K -86 -2%
Canada Life
158
Canada Life
Manitoba, Canada
$182K – – –
PG
159
PEAK6 Group
Illinois
$170K +$166K +3,571 New
AIP
160
Ameritas Investment Partners
Nebraska
$165K +$14K +302 +10%
EWM
161
Evercore Wealth Management
New York
$163K – – –
QI
162
QS Investors
New York
$157K +$153K +3,300 New
CSS
163
Cubist Systematic Strategies
Connecticut
$152K +$81.3K +1,752 +121%
BFEC
164
Benjamin F. Edwards & Company
Missouri
$133K +$14.1K +303 +12%
US Bancorp
165
US Bancorp
Minnesota
$117K -$303K -6,538 -73%
OAM
166
Oppenheimer Asset Management
New York
$114K +$111K +2,399 New
Fifth Third Bancorp
167
Fifth Third Bancorp
Ohio
$89K +$1.81K +39 +2%
AG
168
Advisor Group
Arizona
$88K +$18K +389 +27%
Creative Planning
169
Creative Planning
Kansas
$76K – – –
CG
170
Cutler Group
California
$75K -$396K -8,541 -84%
Zurich Cantonal Bank
171
Zurich Cantonal Bank
Switzerland
$70K +$9.79K +211 +17%
Envestnet Asset Management
172
Envestnet Asset Management
Illinois
$67K +$60.3K +1,299 +1,339%
ES
173
Equitec Specialists
Illinois
$49K -$214K -4,620 -82%
SEC
174
Seven Eight Capital
New York
$46K +$44.4K +957 New
PMFA
175
Plante Moran Financial Advisors
Michigan
$20K – – –
5 6
7
8 9

PCRX Hedge Fund Activity: Q2 2017 in Review

196 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2017, worth a combined $1.97B — up 5% from $1.87B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PCRX positions and 29 closed out — a net gain of 4 holders — while 84 added to existing stakes and 54 trimmed.

The largest buyer was HealthCor Management, adding an estimated $32.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $44.3M sold.

  • 196 institutional investors held Pacira BioSciences (PCRX) as of Q2 2017, up from 192 in Q1 2017.
  • Funds reported $1.97B of Pacira BioSciences stock for Q2 2017, up 5% quarter-over-quarter.
  • 33 funds opened new Pacira BioSciences positions in Q2 2017 and 29 closed out, a net change of +4 holders.
  • The largest Pacira BioSciences buyer in Q2 2017 was HealthCor Management, an estimated $32.2M added.
  • The largest Pacira BioSciences seller in Q2 2017 was Consonance Capital Management, an estimated $44.3M sold.

Based on aggregated 13F filings for Q2 2017.